Seattle Genetic is part of the Puget Sound region cancer research community. The company is widening the use of Adcetris, its first drug, and introducing new drugs. The drug is mostly used to fight lymphomas and currently there are trials of the drugs in more cancer-treatment situations. Adcetris is being tested in various types of lymphomas, and the company is also conducting a trial of the drug for newly diagnosed and previously untreated Hodgkin Lymphoma.
The leading biotechnology company is about to try a drug called 33A which will be used for acute myeloid leukemia. The 33A will be an addition to the 12 drugs that the company has developed. Seattle has also developed a drug for breast cancer and two for bladder cancer. Adcetris is sold in the U.S and Canada, and the sales are expected to range between $255 M and $275M in 2016. The company which has over 800 employees is also said to be hiring 100 employees in the US, most of who will be in operations and 20 employees in the Switzerland’s office.
Seattle Genetics whose headquarters are in Bothell, Washington is committed to developing and commercializing therapies in oncology. It uses antibody-drug conjugates (ADCs) technology to improve treatment and outcomes for people with cancer. The company was founded in 1998 and over the years it has had the following trials-: Non- Hodgkin Lymphoma, Hodgkin Lymphoma, Solid Tumors, Autoimmune Diseases and Acute Myeloid Leukemia.
The person behind the success of the company is Clay Siegall who is a co-founder. The company’s CEO and President is a graduate of the University of Maryland and holds a Ph.D. in Genetics from The George Washington University. He previously worked in National Cancer Institute, Bristol-Myers Squibb Pharmaceutical Research Institute and National Institute of Health. Currently, he is a Director of Mirna Therapeutics Inc and a board member of Alder Biopharmaceutical Inc. Clay was awarded 2012, Pacific Northwest Ernest and Young, Entrepreneur of the Year.